1. Home
  2. NGD vs CYTK Comparison

NGD vs CYTK Comparison

Compare NGD & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGD
  • CYTK
  • Stock Information
  • Founded
  • NGD N/A
  • CYTK 1997
  • Country
  • NGD Canada
  • CYTK United States
  • Employees
  • NGD N/A
  • CYTK N/A
  • Industry
  • NGD
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • NGD
  • CYTK Health Care
  • Exchange
  • NGD Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • NGD 3.9B
  • CYTK 4.6B
  • IPO Year
  • NGD 2004
  • CYTK 2004
  • Fundamental
  • Price
  • NGD N/A
  • CYTK $60.53
  • Analyst Decision
  • NGD Buy
  • CYTK Buy
  • Analyst Count
  • NGD 2
  • CYTK 16
  • Target Price
  • NGD $5.50
  • CYTK $76.73
  • AVG Volume (30 Days)
  • NGD 18.9M
  • CYTK 2.5M
  • Earning Date
  • NGD 10-28-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • NGD N/A
  • CYTK N/A
  • EPS Growth
  • NGD N/A
  • CYTK N/A
  • EPS
  • NGD 0.18
  • CYTK N/A
  • Revenue
  • NGD $1,031,700,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • NGD $51.65
  • CYTK $363.61
  • Revenue Next Year
  • NGD $48.22
  • CYTK $64.08
  • P/E Ratio
  • NGD $39.57
  • CYTK N/A
  • Revenue Growth
  • NGD 27.25
  • CYTK 2635.74
  • 52 Week Low
  • NGD $2.43
  • CYTK $29.31
  • 52 Week High
  • NGD $7.59
  • CYTK $61.48
  • Technical
  • Relative Strength Index (RSI)
  • NGD 77.70
  • CYTK 75.69
  • Support Level
  • NGD $7.17
  • CYTK $47.22
  • Resistance Level
  • NGD $7.59
  • CYTK $61.19
  • Average True Range (ATR)
  • NGD 0.26
  • CYTK 2.20
  • MACD
  • NGD -0.01
  • CYTK 0.65
  • Stochastic Oscillator
  • NGD 76.29
  • CYTK 93.81

About NGD New Gold Inc.

New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: